Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism
April 13 2023 - 8:47AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron-mediated cell death, and immuno-oncology targeted novel
biologics, has selected immune-oncology clinical research
organization (CRO), OncoBay Clinical, to provide comprehensive
clinical and regulatory support for the clinical development
program for its lead drug candidate HSB-1216.
HSB-1216, Hillstream’s most advanced candidate, utilizes
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron-mediated cell death (IMCD) of drug-resistant cancers. As part
of the agreement, OncoBay Clinical’s engagement will provide
comprehensive clinical expertise across data management,
statistical programming, scientific writing, regulatory affairs and
clinical operations services for clinical, and observational
studies. Additionally, OncoBay will leverage the support of a
multitude of top scientific advisors and highly experienced teams
to support Hillstream.
“OncoBay is a natural partner for us, complementing the
oncological expertise of our team,” said Randy Milby, CEO of
Hillstream BioPharma. “With their experience managing the
complexity of oncological research programs and scientific support
from the Moffitt Cancer Center, we believe that the team at OncoBay
is uniquely positioned to support the advancement of the HSB-1216
development program.”
“We are excited to be partnering with Hillstream BioPharma on
the development of HSB-1216,” said Krystyna Kowalczyk, President
and CEO of OncoBay Clinical. “We are confident that our proven
ability to succeed in managing the complexities of oncological
research will enable the accelerated development of Hillstream’s
HSB-1216 program and ultimately make an impact on patients.”
About OncoBay ClinicalOncoBay Clinical is a
global boutique contract research organization (CRO) specializing
in immuno- oncology/cell therapy and other complex oncology
programs. OncoBay offers strategic and full- service custom-curated
solutions for global pharmaceutical and biotech companies looking
to advance their product or device. Originated from Moffitt Cancer
Center, OncoBay embeds scientific expertise, operational excellence
and integration of technology including AI analytics to drive
quality and data integrity. Built on years of oncology expertise,
an advanced technology framework, a highly aligned site network,
and a skilled team of experienced professionals, OncoBay is
committed to operational excellence from start to finish. For more
information, visit Oncobay.com and follow us on Facebook, Twitter
and LinkedIn.
About Hillstream BioPharma, Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing a focused
portfolio of therapeutic candidates targeting drug resistant and
devastating cancers. The Company anticipates submitting an
investigational new drug application and plans to initiate a
clinical study in the second half of 2023 with HSB-1216, which
targets ferroptosis, an emerging new anti-cancer mechanism,
resulting in iron mediated cell death (IMCD) of drug resistant
cancers. The Company’s emerging immuno-oncology pipeline is led by
HSB-3215, a novel anti-HER2 monoclonal antibody targeting unique
epitopes with a novel mechanism of action. The erbB/HER family of
cell surface proteins include well-known and validated drug targets
including HER2 and HER3 found in multiple solid tumors, including
breast, lung, GYN, endocrinological and CNS. For more information,
please visit: www.hillstreambio.com.
Forward Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified using words such as “anticipate,” “believe,”
“forecast,” “estimated” and “intend” or other similar terms or
expressions that concern Hillstream’s expectations, strategy, plans
or intentions. These forward-looking statements are based on
Hillstream’s current expectations and actual results could differ
materially. There are several factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and
trials may not be predictive of future trial results; our clinical
trials may be suspended or discontinued due to unexpected side
effects or other safety risks that could preclude approval of our
product candidates; risks related to business interruptions,
including the outbreak of COVID-19 coronavirus, which could
seriously harm our financial condition and increase our costs and
expenses; dependence on key personnel; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations.
Investors should read the risk factors set forth in our Form 10-K
for the year ended December 31, 2022 and our periodic reports filed
with the Securities and Exchange Commission. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as
of the date hereof, and Hillstream does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Investor Relations
ContactEmail: investorrelations@hillstreambio.comwww.hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Apr 2024 to May 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From May 2023 to May 2024